Core Viewpoint - China National Pharmaceutical Group reported a slight decline in revenue but a modest increase in net profit, indicating resilience amid industry challenges [3] Financial Performance - The company achieved operating revenue of 575.168 billion yuan, a year-on-year decrease of 1.6% [3] - Net profit attributable to shareholders was 7.155 billion yuan, reflecting a year-on-year increase of 1.5% [3] Business Segments - Pharmaceutical distribution revenue was 435.392 billion yuan, accounting for 72.79% of total revenue, down 2.02% year-on-year [3] - Medical device distribution revenue reached 115.538 billion yuan, representing 19.32% of total revenue, also down 2.02% [3] - Retail pharmacy business generated revenue of 38.383 billion yuan, with a year-on-year growth of 6.67%, driven by increased sales in specialty pharmacies [3] Strategic Initiatives - The company is actively pursuing digital transformation and lean management to enhance operational efficiency and compliance risk control amid stricter industry regulations [3] - By 2025, the retail pharmacy segment is expected to turn profitable, with the net loss of Guoda Pharmacy reduced from 1.104 billion yuan to 217 million yuan, showing significant improvement in business structure optimization and cost control [3] Market Outlook - The pharmaceutical distribution and medical device distribution segments are under considerable pressure with declining revenues, while the retail pharmacy segment shows strong growth potential, particularly in specialty pharmacy operations [3] - Overall, the company is continuously adjusting and optimizing its operations to maintain a competitive edge in the future market [3]

Group 1 - The core viewpoint of the article highlights that China National Pharmaceutical Group (国药控股) is expected to achieve revenue growth that outpaces the overall industry by the end of 2025, with a focus on enhancing market share and operational efficiency [1][2] - For the fiscal year ending December 31, 2025, the company reported total revenue of RMB 575.168 billion, a year-on-year decrease of 1.6%, while net profit reached RMB 10.834 billion, reflecting a year-on-year increase of 3.94% [1] - The company proposed a final dividend of RMB 0.69 per share, totaling approximately RMB 2.153 billion, indicating a commitment to returning value to shareholders [1] Group 2 - The company has implemented a cost-leading strategy and lean management practices, resulting in a 0.25 percentage point decrease in overall expense ratio by the end of 2025, effectively offsetting the decline in gross profit [1] - Operating cash flow showed a net inflow of RMB 14.138 billion, an increase of RMB 2.592 billion compared to the previous year, demonstrating effective cash flow management [1] - The company’s accounts receivable growth has significantly narrowed, and the asset-liability ratio decreased by 2.12 percentage points year-on-year, showcasing improved internal governance and resilience against market fluctuations [1] Group 3 - In 2025, the company aims to focus on high-quality development, assessing regional market conditions and competitive landscapes to actively expand market share through reform and innovation [2] - The three main business segments exhibited differentiated development, with the pharmaceutical distribution segment accounting for 72.79% of revenue, a slight decrease of 0.37 percentage points; the medical device distribution segment at 19.32%, down 0.09 percentage points; and the pharmaceutical retail segment at 6.42%, up 0.50 percentage points [2]

Core Viewpoint - The company reported its 1H25 performance, which met expectations, with a slight decline in revenue and net profit compared to the previous year [1][2]. Group 1: Financial Performance - The company's total revenue for 1H25 was 286.04 billion RMB, a year-on-year decrease of 2.95% [1]. - The net profit attributable to shareholders was 3.47 billion RMB, down 6.43% year-on-year, resulting in an earnings per share of 1.11 RMB [1]. - The pharmaceutical distribution revenue was 218.53 billion RMB, a decline of 3.52% year-on-year, primarily due to the ongoing expansion of centralized procurement policies [1]. - The medical device distribution revenue was 57.05 billion RMB, down 2.46% year-on-year, influenced by price reductions from centralized procurement [1]. Group 2: Business Segments - The pharmaceutical retail revenue increased to 17.16 billion RMB, reflecting a year-on-year growth of 3.65%, with an improved operating profit margin of 2.68% [2]. - The number of Guoda Pharmacy stores decreased to 8,591, with a net reduction of 978 stores compared to the end of 2024, but the number of loss-making stores significantly declined [2]. - The company aims to enhance growth through a dual-brand strategy focusing on professional pharmacies and Guoda pharmacies [2]. Group 3: Profitability and Cost Structure - The overall gross margin for 1H25 was 7.11%, down 0.33 percentage points year-on-year, attributed to a slight decrease in the proportion of high-margin businesses [2]. - The sales expense ratio was 2.74%, a decrease of 0.13 percentage points year-on-year, while the management expense ratio was 1.28%, down 0.05 percentage points [2]. Group 4: Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 7.48 billion RMB and 7.93 billion RMB, respectively, both reflecting a 6.0% year-on-year growth [3]. - The current stock price corresponds to a price-to-earnings ratio of 7.4 times for 2025 and 6.9 times for 2026, with a target price of 24.7 HKD, indicating a potential upside of 27.2% [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 2025年6月30 (除特别注明外,金额单位 | | 2025年6月30日 | 2024年12月31日 | | --- | ...

Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, indicating challenges in the current market environment while focusing on sustainable business development and compliance management [1] Group 1: Financial Performance - The company achieved revenue of RMB 286.04 billion, a year-on-year decrease of 2.95% [1] - Profit attributable to shareholders was RMB 3.466 billion, down 6.43% year-on-year [1] - Earnings per share stood at RMB 1.11 [1] Group 2: Business Segments - The pharmaceutical distribution segment maintained stable development, with a revenue share decrease of 0.48 percentage points to 73.62% [1] - The medical device distribution segment saw a slight increase in revenue share by 0.08 percentage points to 19.22% despite a decline in revenue scale [1] - The pharmaceutical retail segment experienced growth, with a revenue share increase of 0.36 percentage points to 5.78% [1] Group 3: Cost Management - The company demonstrated effective cost control, benefiting from reduced financing costs and integrated management measures [2] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, collectively optimizing by 0.2 percentage points [2]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), has no plans to transition into the molecular diagnostics sector, maintaining its focus on pharmaceutical distribution and retail [2] Company Summary - The main business of the company is pharmaceutical distribution and retail [2] - The company responded to an investor inquiry regarding potential transformation into the molecular diagnostics sector, confirming that there are currently no plans for such a transition [2]

Core Viewpoint - The company, China National Pharmaceutical Group (Sinopharm), reported its first decline in both revenue and net profit since its listing in Hong Kong 15 years ago, with a significant drop in net profit exceeding 20% in 2024 due to a slowdown in its high-margin medical device distribution business [1] Financial Performance - In 2024, the total revenue was approximately 458.45 billion, a decrease from 596.57 billion in 2023, marking a decline of about 2.5% [2] - The gross profit for 2024 was 44.26 billion, down from 48.51 billion in 2023, indicating a decrease of approximately 8.5% [2] - The operating profit fell to 16.19 billion from 20.21 billion, a decline of about 20% [2] - The net profit attributable to the parent company was 7.05 billion, down from 9.05 billion, reflecting a decrease of approximately 22% [3] Business Segment Analysis - The pharmaceutical distribution segment generated revenue of approximately 444.37 billion, accounting for about 73.16% of total revenue, with growth driven by an increase in procurement variety [3] - The medical device distribution segment saw revenue of approximately 117.91 billion, a year-on-year decline of 9.44%, primarily due to changes in end-user demand and a decrease in sales of high-margin device categories [3] - The retail segment achieved revenue of 35.98 billion, a slight increase of 0.82%, but the operating profit margin decreased by 2.31 percentage points to 0.90% [4] Subsidiary Performance - Sinopharm's subsidiary, Sinopharm Holding GuoDa Drugstores, experienced a revenue decline of about 8%, while its net profit dropped by 110.36% [4] - Sinopharm's other subsidiary, Sinopharm Weiye, reported a revenue decrease of 7.75% and a net profit decline of 60.88%, with a significant drop in cash flow from operating activities by 285.26% [5]